Q1 Earnings Forecast for GYRE Issued By Noble Financial

Gyre Therapeutics, Inc. (NASDAQ:GYRE) – Equities research analysts at Noble Financial issued their Q1 2026 earnings estimates for Gyre Therapeutics in a note issued to investors on Tuesday, September 9th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings per share of $0.12 for the quarter. Noble Financial also issued estimates for Gyre Therapeutics’ Q2 2026 earnings at $0.13 EPS, Q3 2026 earnings at $0.13 EPS and Q4 2026 earnings at $0.14 EPS.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings data on Monday, August 11th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). Gyre Therapeutics had a net margin of 4.08% and a return on equity of 7.67%. The business had revenue of $26.77 million for the quarter, compared to the consensus estimate of $30.80 million.

Separately, HC Wainwright initiated coverage on shares of Gyre Therapeutics in a research note on Tuesday, August 26th. They issued a “buy” rating and a $18.00 target price on the stock. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $18.00.

Gyre Therapeutics Trading Up 6.5%

Shares of GYRE opened at $8.17 on Wednesday. Gyre Therapeutics has a twelve month low of $6.11 and a twelve month high of $19.00. The company has a market cap of $786.85 million, a P/E ratio of 817.82 and a beta of 1.86. The company’s fifty day simple moving average is $7.62 and its 200-day simple moving average is $8.63.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its stake in Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after buying an additional 1,402 shares during the period. JPMorgan Chase & Co. increased its stake in Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after buying an additional 2,961 shares during the period. Wells Fargo & Company MN increased its stake in Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after buying an additional 913 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after buying an additional 3,244 shares during the period. Finally, Advantage Alpha Capital Partners LP increased its stake in Gyre Therapeutics by 54.0% in the 1st quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company’s stock worth $105,000 after buying an additional 4,790 shares during the period. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.